Medical Profession
A new era in multiple sclerosis
Momentum continues to build in the use of high-efficacy, disease modifying therapies (DMTs) as a first choice for treating multiple sclerosis. How is this being influenced by the availability of anti-CD20s, a new class of DMT? Will future new therapy classes change the paradigm even further?
